Clinical Landscape of T Cell Bispecifics in Solid Tumors

Explore the emerging field of T cell bispecific immunotherapies in solid tumor oncology through this 27-minute webinar presented by Dr. Bilal A. Siddiqui, Assistant Professor in Genitourinary Medical Oncology at the University of Texas MD Anderson. Learn about the mechanism of action of T cell bispecifics, a promising class of immunotherapies that have demonstrated survival benefits in hematologic malignancies and are now being investigated in solid tumors. Examine the toxicity profiles associated with these treatments and understand the mechanisms of resistance that can limit their effectiveness. Discover how lessons learned from hematologic malignancies and ongoing clinical trials are being applied to advance the development of T cell bispecifics in solid tumor oncology. Gain insights from Dr. Siddiqui's extensive clinical and translational research experience, including his work as principal investigator on multiple clinical trials of T cell engagers in prostate cancer and his expertise in immune-mediated toxicities. The presentation covers biomarker-rich trial strategies, novel immunotherapy approaches, and the identification of mechanistic biomarkers for early detection and intervention of treatment-related complications. Understand the current clinical landscape and future directions for maximizing efficacy while minimizing toxicities of these innovative immunotherapy strategies in cancer patients. PACE credits are available for registered participants through April 30, 2027.